Eucalyptus says weight loss drugs sales are booming
A steady supply of weight-loss drugs Wegovy and Mounjaro has helped lift Eucalyptus’ revenue from $78 million to $121 million ...
The American Journal of Managed Care3d
Medicare Part D Spending Trends for Type 2 Diabetes Medications
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
NJBIZ4d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
MM&M4d
What did Big Pharma CEOs get paid in 2024?
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
6 Stocks to Buy as European Markets Soar
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
Medicare spending on diabetes drugs surged over 5 years, US report shows
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
BioSpace4d
Congress Re-Introduces EPIC Act to Remove IRA’s ‘Pill Penalty’
While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it ...
Endocrinology Advisor5d
Novo Nordisk’s Wegovy, Ozempic No Longer in Short Supply, According to FDA
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
EurekAlert!5d
The Obesity Society commends FDA's resolution of obesity drug shortages, calls for enforcement against unauthorized compounding
ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two ...
Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update
We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...
SSH's Dr. Todd Ellerin explains lawsuit against FDA over shortage of weight-loss drugs
Dr. Todd Ellerin says the compounded pharmacy drugs are regulated on the state level, but most do not possess FDA regulation like brand name drugs ...